Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2
Conclusion:
Participants had reductions in hearing difficulty during treatment with bevacizumab, suggesting that patients subjectively experience hearing-related benefit mirroring clinical hearing assessments. We suspect the lack of significant reduction in tinnitus distress is related to small sample size and low intensity of distress in our sample. These data highlight the usefulness of PRO measures to assess benefits of treatment in the setting of NF2-associated hearing loss.
Source: Otology and Neurotology - Category: ENT & OMF Tags: Tumors of the Ear and Cranial Base Source Type: research
More News: Avastin | Brain | Clinical Trials | ENT & OMF | Neurofibromatosis | Neurology | Statistics | Study | Tinnitus